Together we are beating cancer

Donate now

Palliative care

Showing 4 out of 4 results
Cancer Research UK logo

Elderly patients with advanced non small cell lung cancer (NSCLC) who developed a rash within 28 days of receiving the targeted drug erlotinib (Tarceva) survived on average 6.2 months, compared to 4.1 months for patients who were given a placebo, results from a major phase III Cancer Research UK-funded trial show today (Tuesday). Elderly patients with advanced non small cell lung cancer (NSCLC) who developed a rash within 28 days of receiving the targeted drug erlotinib (Tarceva) survived on average 6.2 months, compared to 4.1 months for patients who were given a placebo, results from a major phase III Cancer Research UK-funded trial show today (Tuesday).

by Cancer Research UK | News | 16 October 2012

16 October 2012

Cancer Research UK logo

Two grants have been awarded from a programme of nearly Ј5 million to boost research into supportive and palliative care for British cancer patients. Two grants have been awarded from a programme of nearly Ј5 million to boost research into supportive and palliative care for British cancer patients.

by Cancer Research UK | News | 12 June 2006

12 June 2006